◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 4587

PeptiDream Inc. (4587) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

PeptiDream Inc. (4587) operates in the Biotechnology industry and is headquartered in Kawasaki, Japan with about 745 employees. Its market capitalization is roughly JPY 127 billion. In the fiscal year ended 2025-12-31, 4587 reported JPY 18.5B in revenue and (JPY 3.7B) in net income.

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.

Interactive charts & full statements →

4587 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueJPY 18.5BJPY 46.7BJPY 28.7BJPY 26.9B
Gross ProfitJPY 7.5BJPY 34.5BJPY 17.2BJPY 18.1B
Operating Income (EBIT)(JPY 5.0B)JPY 21.1BJPY 6.8BJPY 9.0B
Net Income(JPY 3.7B)JPY 15.0BJPY 3.0BJPY 7.6B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4587 Free Cash Flow History

4587 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsJPY 77.0BJPY 92.8BJPY 69.5BJPY 63.9B
Total LiabilitiesJPY 25.5BJPY 36.0BJPY 29.1BJPY 31.8B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4587 viewer.

Other Companies in Biotechnology

← 4578All “0-9” companies4595 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.